Marie Lindner
Directeur/Membre du Conseil chez Giiant Pharma, Inc.
Profil
Marie A.
Lindner was the founder of Embera NeuroTherapeutics, Inc. founded in 2005, where she held the title of Director & Medical Monitor.
Currently, she is an Independent Director at Orthogon Therapeutics LLC, Giiant Pharma, Inc., BioCurate Pty Ltd., and a Scientific Advisor at FutuRx Ltd.
In the past, she held senior positions at Shire Pharmaceuticals, Inc., Rhône-Poulenc, Inc., GlaxoSmithKline LLC, Trino Therapeutics Ltd., Fibrocell Science, Inc., Elan Drug Delivery, Inc., Novartis AG, BTG Ltd., The Biotechnology Greenhouse Corp.
of Southeastern PA, BTG International, Inc., and Elan Corp.
She has also earned an undergraduate degree from Washington University in St. Louis and a graduate degree from Rosalind Franklin University of Medicine & Science.
Postes actifs de Marie Lindner
| Sociétés | Poste | Début |
|---|---|---|
Giiant Pharma, Inc.
 Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Orthogon Therapeutics LLC
 Orthogon Therapeutics LLC Pharmaceuticals: MajorHealth Technology Orthogon Therapeutics LLC is a privately held R&D firm that specializes in drug discovery and development. The company is based in Canton, MA. The company is headquartered in the biotech hub of Greater Boston and has a branch in Leuven. Orthogon uses an innovative structure-based and biophysics platform to design novel medicines. The company's portfolio of infectious disease assets includes antiviral therapeutics, with a lead program being a first-in-class, orally administrable small molecule inhibitor of BK virus replication. Orthogon has secured over $12.50m in investment to date and has additional discovery programs, including a treatment for antibiotic-resistant bacterial infections. The company was founded by Ali Munawar, a veteran biotech entrepreneur, and experienced drug discovery scientists with a mission to prolong and improve patient quality of life. | Directeur/Membre du Conseil | 15/11/2021 |
| BioCurate Pty Ltd. | Directeur/Membre du Conseil | - |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Consultant / Advisor | - |
Anciens postes connus de Marie Lindner
| Sociétés | Poste | Fin |
|---|---|---|
The Biotechnology Greenhouse Corp. of Southeastern PA
 The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania. | Private Equity Investor | 01/07/2012 |
| FIBROCELL SCIENCE, INC. | Corporate Officer/Principal | 31/12/2006 |
BTG International, Inc.
 BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Corporate Officer/Principal | - |
Elan Drug Delivery, Inc.
 Elan Drug Delivery, Inc. Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Elan Drug Delivery, Inc. is engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The company is based in King Of Prussia, PA. | Corporate Officer/Principal | 31/12/2002 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | 31/12/1999 |
Formation de Marie Lindner
| Washington University in St. Louis | Undergraduate Degree |
| Rosalind Franklin University of Medicine & Science | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| ELAN CORPORATION | Health Technology |
| Entreprise privées | 14 |
|---|---|
Fibrocell Science, Inc.
 Fibrocell Science, Inc. Pharmaceuticals: MajorHealth Technology Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA. | Health Technology |
Elan Drug Delivery, Inc.
Elan Drug Delivery, Inc. Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Elan Drug Delivery, Inc. is engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The company is based in King Of Prussia, PA. | Health Technology |
Embera NeuroTherapeutics, Inc.
 Embera NeuroTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Embera NeuroTherapeutics, Inc. develops treatments for smoking cessation, cocaine dependence and other addictions. The company was founded by Nicholas Edward Goeders and Marie A. Lindner in 2005 and is headquartered in Sudbury, MA. | Health Technology |
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
The Biotechnology Greenhouse Corp. of Southeastern PA
The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
BTG International, Inc.
BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Finance |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
| Rhône-Poulenc, Inc. | Process Industries |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Trino Therapeutics Ltd.
 Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Health Technology |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Finance |
Orthogon Therapeutics LLC
Orthogon Therapeutics LLC Pharmaceuticals: MajorHealth Technology Orthogon Therapeutics LLC is a privately held R&D firm that specializes in drug discovery and development. The company is based in Canton, MA. The company is headquartered in the biotech hub of Greater Boston and has a branch in Leuven. Orthogon uses an innovative structure-based and biophysics platform to design novel medicines. The company's portfolio of infectious disease assets includes antiviral therapeutics, with a lead program being a first-in-class, orally administrable small molecule inhibitor of BK virus replication. Orthogon has secured over $12.50m in investment to date and has additional discovery programs, including a treatment for antibiotic-resistant bacterial infections. The company was founded by Ali Munawar, a veteran biotech entrepreneur, and experienced drug discovery scientists with a mission to prolong and improve patient quality of life. | Health Technology |
Giiant Pharma, Inc.
Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Health Technology |
| BioCurate Pty Ltd. |